(NYSEMKT: NNVC) Nanoviricides's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.8%.
Nanoviricides's earnings in 2026 is -$8,318,441.On average, 4 Wall Street analysts forecast NNVC's earnings for 2026 to be -$10,352,643, with the lowest NNVC earnings forecast at -$12,274,598, and the highest NNVC earnings forecast at -$8,162,910. On average, 4 Wall Street analysts forecast NNVC's earnings for 2027 to be -$10,132,374, with the lowest NNVC earnings forecast at -$9,735,026, and the highest NNVC earnings forecast at -$10,430,385.
In 2028, NNVC is forecast to generate -$9,471,567 in earnings, with the lowest earnings forecast at -$9,100,133 and the highest earnings forecast at -$9,750,143.